Jill Giordano Farmer
Neurology · Philadelphia, PANPI 1851548671
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $850,929 of the $1,179,649 with a category attached, or 72.1%. It is spread thinly across 26 manufacturers, the largest accounting for just 18.1%. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,284 payments — averaging $918.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$214K
- Acadia Pharmaceuticals Inc$207K
- Neurocrine Biosciences, Inc.$178K
- MDD US Operations, LLC$164K
- AbbVie$131K
- Teva Pharmaceuticals USA, Inc.$97K
- plus $188K from 20 others
Across 32 payments — averaging $3311.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$106K
What the payments were for
- Consulting fees$206,87318%
- Speaking & faculty fees$850,92972%
- Travel & lodging$96,8698%
- Food & beverage$21,4802%
- Education$3,4990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 186 | $213,977 |
| Acadia Pharmaceuticals Inc | 225 | $206,787 |
| Neurocrine Biosciences, Inc. | 165 | $177,882 |
| MDD US Operations, LLC | 214 | $164,184 |
| AbbVie(2 entities) | 140 | $131,408 |
| Teva Pharmaceuticals USA, Inc. | 117 | $97,465 |
| Amneal Pharmaceuticals LLC | 77 | $88,078 |
| Acorda Therapeutics, Inc | 29 | $27,036 |
| Global Kinetics USA Corporation | 8 | $20,150 |
| Sunovion Pharmaceuticals Inc. | 22 | $15,805 |
| Medtronic(2 entities) | 25 | $12,934 |
| Tanabe Pharma America, Inc. | 11 | $11,084 |
| Merz Pharmaceuticals, LLC | 21 | $6,031 |
| Lundbeck LLC | 15 | $2,800 |
| Adamas Pharmaceuticals, Inc. | 4 | $2,587 |
| Boston Scientific | 5 | $457 |
| Supernus Pharmaceuticals, Inc. | 4 | $324 |
| Dr.reddy's Laboratories,inc. | 1 | $158 |
| Revance Therapeutics, Inc. | 2 | $153 |
| GE HealthCare | 1 | $93 |
| Avanir Pharmaceuticals, Inc. | 5 | $71 |
| UCB, Inc. | 2 | $67 |
| Abbott | 1 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Greenwich Biosciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOURIANZ$211,459
- NUPLAZID$192,479
- INGREZZA$148,604
- GOCOVRI$113,872
- Duopa$92,986
- CREXONT$74,740
- AUSTEDO$53,396
- Austedo XR$42,230
- INBRIJA$26,575
- ONGENTYS$23,438
- PERSONAL KINETIGRAPH (PKG)$22,750
- APOKYN$22,230
- VYALEV$19,080
- ACTIVA$8,829
- LATUDA$8,057
- XEOMIN$5,688
- DISEASE EDUCATION$5,000
- KYNMOBI$4,775
- Percept$3,375
- NORTHERA$2,625
How this compares
$1,179,649 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 116 | $643,716 |
| NourianzIstradefylline | 62 | $200,151 |
| GocovriAmantadine Hcl | 47 | $124,870 |
| InbrijaLevodopa | 20 | $92,687 |
| RytaryCarbidopa/Levodopa | 57 | $73,229 |
| NeuproRotigotine | 35 | $52,674 |
| Rasagiline Mesylate | 158 | $37,572 |
| OngentysOpicapone | 28 | $34,881 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 466 | $23,723 |
| CrexontCarbidopa/Levodopa | 18 | $17,595 |
| Rivastigmine | 33 | $8,693 |
| Pramipexole ErPramipexole Di-Hcl | 15 | $7,777 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 57 | $5,549 |
| Selegiline Hcl | 39 | $5,476 |
| RivastigmineRivastigmine Tartrate | 62 | $4,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $206,787 | $643,716116 claims |
| Kyowa Kirin, Inc.Nourianz | $213,977 | $200,15162 claims |
| MDD US Operations, LLCGocovri | $164,184 | $124,87047 claims |
| Acorda Therapeutics, IncInbrija | $27,036 | $92,68720 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $88,078 | $90,82475 claims |
| UCB, Inc.Neupro | $67 | $52,67435 claims |
| Neurocrine Biosciences, Inc.Ongentys | $177,882 | $34,88128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
- Michelle DoughertyPhiladelphia$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.